Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
MSC group:Intravenous infusion of MSC based on conventional treatments
Sponsors
The First Hospital of Changsha
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed as severe or critical COVID-19; or patients who have turned negative for viral nucleic acid detection but still have the following severe or critical manifestations: According to the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Version 6)" promulgated by the National Health Commission, any of the following is confirmed to be diagnosed as severe COVID-19: 1) shortness of breath, RR >=30 times / minute; 2) in a resting state , Oxygen saturation<=93%; 3) arterial blood oxygen partial pressure (PaO2) / oxygen concentration (FiO2) <=300mmHg (1mmHg = 0.133kPa). The diagnosis of critical COVID-19 is consistent with any of the following: 1) respiratory failure occurs and requires mechanical ventilation; 2) shock occurs; 3) combined organ failure requires ICU monitoring and treatment; 2. Informed consent, voluntary participation and signing of informed consent by patients (or entrusted agents).
Exclusion criteria
Exclusion criteria: (1) Past medical history of pulmonary embolism; (2) Patients infected with human immunodeficiency virus (HIV); (3) Patients with malignant tumors: Patients with cervical carcinoma in situ, skin non metastatic squamous or basal cell carcinoma after complete treatment are excluded; (4) pregnant and lactating women; (5) Other situations that the clinician considers unsuitable.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Oxygenation index (arterial oxygen partial pressure (PaO2) / oxygen concentration (FiO2));Conversion rate from serious to critical patients;Conversion rate and conversion time from critical to serious patients;Mortality in serious and critical patients; | — |
Secondary
| Measure | Time frame |
|---|---|
| Low-dose spiral CT of the lung (in special cases, the investigator decides whether to use other imaging tests based on the actual situation of the patient);Peak flow meter;COVID-19 nucleic acid detection;Peripheral blood lymphocyte subsets (total T cells, CD4 + T cells, CD8 + T cells, B cells, NK cells, etc.);Cytokine detection (IL-1beta, IL-2, IL-6, IL-10, TNFalpha, etc.);Sequential organ failure assessment;APACHE II score;Acute lung injury score;Blood routine;C-reactive protein;liver and kidney function;electrolyte;myocardial enzymes;procalcitonin;coagulation function;D-dimer;arterial blood gas analysis;Respiratory function support types and parameters; | — |
Countries
China
Contacts
Public ContactXie yuanlin
The First Hospital of Changsha
Outcome results
None listed